Exploration of Neuroscience

Table 2. Demographic characteristics of study subjects

Characteristics	Number (percentage)
Total study subjects, n	151
Mixed pain diagnosis (excluded), n	17
Number of female subjects, n (%)	94 (62.3%)
Mean age, years (range)	58.5 (26−90)
Most common causes of NeP, n = 93
Trigeminal neuralgia	48 (51.6%)
Peripheral neuropathy (including diabetes)	14 (15.0%)
Central pain	11 (11.8%)
Post-herpetic neuralgia	10 (10.8%)
Others	10 (10.8%)
Most common causes of NoP, n = 41
Musculoskeletal pain	19 (46.3%)
Arthritis	17 (41.5%)
Others	5 (12.2%)
Pain diagnosis	NeP	NoP
Subjects, n (%)	93 (61.6%)	41 (27.1%)
Female subjects, n (%)	52 (55.9%)	30 (73.2%)
Mean age, years	61.8	53.9
Mean current pain, VAS/NRS score ± SD (range)	4.75 ± 2.96 (0–10)	4.54 ± 2.71 (0–9)

Return to article view

NeP: neuropathic pain; NoP: nociceptive pain; NRS: numeric rating scale; SD: standard deviation; VAS: visual analogue scale

Declarations

Acknowledgments

The authors would like to thank Dr. Moritz Kurtz for translating the PD-Q from German to Chinese. The authors would also like to thank all subjects and study personnel for participating in this study.

Author contributions

HL, JWYI, JMKL, GKWL, CCFL, RL, VM, THT, CPW, SHSW, CMC, and RF: Conceptualization, Investigation, Data curation, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

RF has received consultancy and speaker fees within the past 2 years from AOP Orphan, Grünenthal GmbH, Eli Lilly and Company, Merck Consumer Health, Mitsubishi Tanabe Pharma, Pfizer, Roche Pharma, and Scilex Pharmaceuticals.

Ethical approval

This study’s protocol was approved by the respective Hong Kong Hospital Authority cluster or institutional review boards (IRB) of the six sites participating in the study.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This study was funded by the Multidisciplinary Panel on Neuropathic Pain of Hong Kong and Pfizer Hong Kong.

Copyright

References

IASP. Terminology [Internet]. Washington: International Association for the Study of Pain; c2021 [cited 2023 Nov 20]. Available from: https://www.iasp-pain.org/terminology

Freynhagen R, Parada HA, Calderon-Ospina CA, Chen J, Rakhmawati Emril D, Fernández-Villacorta FJ, et al. Current understanding of the mixed pain concept: a brief narrative review. Curr Med Res Opin. 2019;35:1011−8. [DOI] [PubMed]

Spahr N, Hodkinson D, Jolly K, Williams S, Howard M, Thacker M. Distinguishing between nociceptive and neuropathic components in chronic low back pain using behavioural evaluation and sensory examination. Musculoskelet Sci Pract. 2017;27:40−8. [DOI] [PubMed] [PMC]

Cheung CW, Choi SW, Wong SSC, Lee Y, Irwin MG. Changes in Prevalence, Outcomes, and Help-seeking Behavior of Chronic Pain in an Aging Population Over the Last Decade. Pain Pract. 2017;17:643−54. [DOI] [PubMed]

Wong SSC, Choi SW, Cheung CW. A comparison of chronic pain with and without neuropathic characteristics in a Hong Kong Chinese population: An analysis of pain related outcomes and patient help seeking behaviour. PLoS One. 2018;13:e0204054. [DOI] [PubMed] [PMC]

Rifbjerg-Madsen S, Christensen AW, Christensen R, Hetland ML, Bliddal H, Kristensen LE, et al. Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. PLoS One. 2017;12:e0180014. [DOI] [PubMed] [PMC]

Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, et al. Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. Support Care Cancer. 2017;25:3759−67. [DOI] [PubMed] [PMC]

Gudala K, Bansal D, Vatte R, Ghai B, Schifano F, Boya C. High Prevalence of Neuropathic Pain Component in Patients with Low Back Pain: Evidence from Meta-Analysis. Pain Physician. 2017;20:343−52. [PubMed]

Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018;41:60−3. [DOI] [PubMed] [PMC]

10.

Nishikawa N, Nomoto M. Management of neuropathic pain. J Gen Fam Med. 2017;18:56−60. [DOI] [PubMed] [PMC]

11.

Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147−57. [DOI] [PubMed]

12.

Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29−36. [DOI] [PubMed]

13.

Portenoy R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22:1555−65. [DOI] [PubMed]

14.

Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911−20. [DOI] [PubMed]

15.

Hüllemann P, Keller T, Kabelitz M, Freynhagen R, Tölle T, Baron R. Pain Drawings Improve Subgrouping of Low Back Pain Patients. Pain Pract. 2017;17:293−304. [DOI] [PubMed]

16.

Tampin B, Bohne T, Callan M, Kvia M, Melsom Myhre A, Neoh EC, et al. Reliability of the English version of the painDETECT questionnaire. Curr Med Res Opin. 2017;33:741−8. [DOI] [PubMed]

17.

De Andrés J, Pérez-Cajaraville J, Lopez-Alarcón MD, López-Millán JM, Margarit C, Rodrigo-Royo MD, et al. Cultural Adaptation and Validation of the painDETECT Scale Into Spanish. Clin J Pain. 2012;28:243−53. [DOI] [PubMed]

18.

Matsubayashi Y, Takeshita K, Sumitani M, Oshima Y, Tonosu J, Kato S, et al. Validity and reliability of the Japanese version of the painDETECT questionnaire: a multicenter observational study. PLoS One. 2013;8:e68013. [DOI] [PubMed] [PMC]

19.

Timmerman H, Wolff AP, Bronkhorst EM, Wilder-Smith OHG, Schenkels MJ, van Dasselaar NT, et al. Avoiding Catch-22: validating the PainDETECT in a in a population of patients with chronic pain. BMC Neurol. 2018;18:91. [DOI] [PubMed] [PMC]

20.

Sung JK, Choi JH, Jeong J, Kim WJ, Lee DJ, Lee SC, et al. Korean Version of the painDETECT Questionnaire: A Study for Cultural Adaptation and Validation. Pain Pract. 2017;17:494−504. [DOI] [PubMed]

21.

Alkan H, Ardic F, Erdogan C, Sahin F, Sarsan A, Findikoglu G. Turkish Version of the painDETECT Questionnaire in the Assessment of Neuropathic Pain: A Validity and Reliability Study. Pain Med. 2013;14:1933−43. [DOI] [PubMed]

22.

Gudala K, Ghai B, Bansal D. Neuropathic Pain Assessment with the PainDETECT Questionnaire: Cross-Cultural Adaptation and Psychometric Evaluation to Hindi. Pain Pract. 2017;17:1042−9. [DOI] [PubMed]

23.

Abu-Shaheen A, Yousef S, Riaz M, Nofal A, AlFayyad I, Khan S, et al. Testing the validity and reliability of the Arabic version of the painDETECT questionnaire in the assessment of neuropathic pain. PLoS One. 2018;13:e0194358. [DOI] [PubMed] [PMC]

24.

Gomez MFCS, Gomez MFAS, Gomez MHS, Que JC, Rosales RL. painDETECT Questionnaire Filipino version: Transcultural adaptation and validation in two widely spoken regional languages (Tagalog and Cebuano). Neurol Asia. 2019;24:21−30.

25.

Freynhagen R, Tölle TR, Gockel U, Baron R. The painDETECT project − far more than a screening tool on neuropathic pain. Curr Med Res Opin. 2016;32:1033−57. [DOI] [PubMed]

26.

Chan A, Wong S, Chen PP, Tsoi TH, Lam J, Ip WY, et al. Validation study of the Chinese Identification Pain Questionnaire for neuropathic pain. Hong Kong Med J. 2011;17:297−300. [PubMed]

27.

Zhang RF, Leung YY. SAT0470 Validity and Reliability of The Chinese Version of The Paindetect Questionnaire in Subjects with Knee Osteoarthritis. Ann Rheum Dis. 2016;75:840−1. [DOI]

28.

Gálvez R, Marsal C, Vidal J, Ruiz M, Rejas J. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain. 2007;11:244−55. [DOI] [PubMed]

29.

Ibor PJ, Sánchez-Magro I, Villoria J, Leal A, Esquivias A. Mixed Pain Can Be Discerned in the Primary Care and Orthopedics Settings in Spain: A Large Cross-Sectional Study. Clin J Pain. 2017;33:1100−8. [DOI] [PubMed]

30.

Keller T, Freynhagen R, Tölle TR, Liwowsky I, Möller P, Hüllemann P, et al. A retrospective analysis of the long-term test−retest stability of pain descriptors of the painDETECT questionnaire. Curr Med Res Opin. 2016;32:343−9. [DOI] [PubMed]

31.

Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al.; ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94−104. [DOI] [PubMed]

32.

Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the Process of Cross-Cultural Adaptation of Self-Report Measures. Spine (Phila Pa 1976). 2000;25:3186−91. [DOI] [PubMed]

33.

Walker SM, Peters J, Verriotis M, Farag F, Jay MA, Howard RF. Sensitivity and Specificity of a Neuropathic Screening Tool (Self-Report Leeds Assessment of Neuropathic Symptoms and Signs, S-LANSS) in Adolescents With Moderate-Severe Chronic Pain. J Pain. 2024;25:451−65. [DOI] [PubMed]